Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation of caspase-3 and prevention of mitochondrial cytochrome c release.
BACKGROUND
Apoptosis plays a key role in cell death observed in neurodegenerative diseases marked by a progressive loss of neurons as seen in Alzheimer's disease. Although the exact cause of apoptosis is not known, a number of factors such as free radicals, insufficient levels of nerve growth factors and excessive levels of glutamate have been implicated. We and others, have previously reported that in a stable HT22 neuronal cell line, glutamate induces apoptosis as indicated by DNA fragmentation and up- and down-regulation of Bax (pro-apoptotic), and Bcl-2 (anti-apoptotic) genes respectively. Furthermore, these changes were reversed/inhibited by estrogens. Several lines of evidence also indicate that a family of cysteine proteases (caspases) appear to play a critical role in neuronal apoptosis. The purpose of the present study is to determine in primary cultures of cortical cells, if glutamate-induced neuronal apoptosis and its inhibition by estrogens involve changes in caspase-3 protease and whether this process is mediated by Fas receptor and/or mitochondrial signal transduction pathways involving release of cytochrome c.


RESULTS
In primary cultures of rat cortical cells, glutamate induced apoptosis that was associated with enhanced DNA fragmentation, morphological changes, and up-regulation of pro-caspase-3. Exposure of cortical cells to glutamate resulted in a time-dependent cell death and an increase in caspase-3 protein levels. Although the increase in caspase-3 levels was evident after 3 h, cell death was only significantly increased after 6 h. Treatment of cells for 6 h with 1 to 20 mM glutamate resulted in a 35 to 45% cell death that was associated with a 45 to 65% increase in the expression of caspase-3 protein. Pretreatment with caspase-3-protease inhibitor z-DEVD or pan-caspase inhibitor z-VAD significantly decreased glutamate-induced cell death of cortical cells. Exposure of cells to glutamate for 6 h in the presence or absence of 17beta-estradiol or Delta8, 17beta-estradiol (10 nM-10 microM) resulted in the prevention of cell death and was associated with a significant dose-dependent decrease in caspase-3 protein levels, with Delta8, 17beta-E2 being more potent than 17beta-E2. Protein levels of Fas receptor remained unchanged in the presence of glutamate. In contrast, treatment with glutamate induced, in a time-dependent manner, the release of cytochrome c into the cytosol. Cytosolic cytochrome c increased as early as 1.5 h after glutamate treatment and these levels were 5 fold higher after 6 h, compared to levels in the untreated cells. Concomitant with these changes, the levels of cytochrome c in mitochondria decreased significantly. Both 17beta-E2 and Delta8, 17beta-E2 reduced the release of cytochrome c from mitochondria into the cytosol and this decrease in cytosolic cytochrome c was associated with inhibition of glutamate-induced cell death.


CONCLUSIONS
In the primary cortical cells, glutamate-induced apoptosis is accompanied by up-regulation of caspase-3 and its activity is blocked by caspase protease inhibitors. These effects of glutamate on caspase-3 appear to be independent of changes in Fas receptor, but are associated with the rapid release of mitochondrial cytochrome c, which precedes changes in caspase-3 protein levels leading to apoptotic cell death. This process was differentially inhibited by estrogens with the novel equine estrogen Delta8, 17beta-E2 being more potent than 17beta-E2. To our knowledge, this is the first study to demonstrate that equine estrogens can prevent glutamate-induced translocation of cytochrome c from mitochondria to cytosol in rat primary cortical cells.
Zhang
YueMei
Y
Department of Obstetrics and Gynecology, University of Toronto, Toronto, Canada. ymzhang@hotmail.com <ymzhang@hotmail.com>
Bhavnani
Bhagu R
BR
D000818:Animals; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism*; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000187:drug effects* / Q000201:enzymology; D045304:Cytochromes c / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D018698:Glutamic Acid / Q000633:toxicity*; D006736:Horses; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000201:enzymology; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley
D004791:Enzyme Inhibitors; D004967:Estrogens; D018698:Glutamic Acid; D045304:Cytochromes c; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases
Nature. 1996 Apr 25;380(6576):723-6
8614469
J Soc Gynecol Investig. 2003 Jul;10(5):302-8
12853093
Cell. 1996 Jul 12;86(1):147-57
8689682
Neuroreport. 1996 Sep 2;7(13):2071-7
8930961
Endocrinology. 1997 Jan;138(1):101-6
8977391
Fertil Steril. 1997 Jan;67(1):57-62
8986684
Adv Neurol. 1997;72:95-101
8993688
EMBO J. 1997 May 15;16(10):2794-804
9184224
J Biol Chem. 1997 Aug 15;272(33):20317-20
9252332
EMBO J. 1997 Aug 1;16(15):4639-49
9303308
J Soc Gynecol Investig. 2000 May-Jun;7(3):175-83
10865186
J Biol Chem. 2000 Sep 29;275(39):30586-96
10859318
J Biol Chem. 2000 Nov 24;275(47):37159-66
10980192
Cell Mol Life Sci. 2001 Apr;58(4):636-44
11361096
FEBS Lett. 2001 May 18;497(1):1-5
11376653
J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):473-82
12943738
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5
15024130
BMC Neurosci. 2003 Dec 23;4:32
14693041
Neurosci Lett. 2004 Sep 16;368(1):87-91
15342140
J Neurochem. 1984 Jan;42(1):1-11
6139418
Cell. 1991 Jul 26;66(2):233-43
1713127
J Clin Endocrinol Metab. 1993 Oct;77(4):1095-7
8408459
Science. 1993 Oct 29;262(5134):689-95
7901908
N Engl J Med. 1994 Mar 3;330(9):613-22
7905600
Prog Brain Res. 1994;100:47-51
7938533
Brain Res. 1994 Jul 25;652(1):169-73
7953717
J Biol Chem. 1994 Dec 9;269(49):30761-4
7983002
Science. 1995 Mar 10;267(5203):1445-9
7878463
Science. 1995 Mar 10;267(5203):1456-62
7878464
Nature. 1995 May 4;375(6526):78-81
7536900
Nature. 1995 May 4;375(6526):81-3
7536901
Cell. 1995 Jun 2;81(5):801-9
7774019
Nature. 1995 Jul 6;376(6535):37-43
7596430
Cell. 1995 Aug 11;82(3):349-52
7634323
Neurochem Int. 1994 May;24(5):485-93
7647702
Biochem Biophys Res Commun. 1995 Nov 13;216(2):473-82
7488136
EMBO J. 1995 Dec 15;14(24):6148-56
8557034
J Biol Chem. 1996 Jan 26;271(4):1841-4
8567626
J Neurosci Res. 1995 Dec;42(5):674-83
8600300
EMBO J. 1996 Mar 1;15(5):1012-20
8605870
Biochem J. 1997 Aug 15;326 ( Pt 1):1-16
9337844
Cell. 1997 Nov 14;91(4):479-89
9390557
EMBO J. 1998 Jan 2;17(1):37-49
9427739
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002
9560217
Free Radic Biol Med. 1998 Jun;24(9):1375-89
9641255
Genes Cells. 1998 May;3(5):297-306
9685181
J Biol Chem. 1998 Oct 9;273(41):26566-70
9756894
Brain Res. 1998 Nov 9;810(1-2):87-92
9813255
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6
9843949
Cell Death Differ. 1998 Dec;5(12):1004-16
9894607
Biochem Biophys Res Commun. 1999 Mar 16;256(2):381-4
10079193
J Neurochem. 1999 Apr;72(4):1552-63
10098861
Eur J Neurosci. 1999 Mar;11(3):1067-72
10103099
Cell. 1999 Apr 30;97(3):395-406
10319819
J Neurochem. 1999 Jun;72(6):2601-9
10349872
J Soc Gynecol Investig. 2001 Jul-Aug;8(4):245-54
11525901
Br J Pharmacol. 2001 Nov;134(6):1263-70
11704646
Menopause. 2001 Nov-Dec;8(6):408-19
11723413
J Neurochem. 2002 Jan;80(2):207-18
11902111
FEBS Lett. 2002 Jun 19;521(1-3):53-6
12067725
J Neurosci. 2002 Sep 1;22(17):7650-61
12196588
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2842-7
12604781
J Biol Chem. 1996 Jul 12;271(28):16720-4
8663294